Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati

Abdullahi Ahmed Momamed; Thomas Krøigård; Thomas Agerbo Gaist; Lars Kjøbsted Markvardsen; Søren Hein Sindrup; Henning Andersen; Morten Blaabjerg

Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati

Translated title of the contribution: Antibodies in patients with chronic inflammatory demyelinating polyneuropathy

Abdullahi Ahmed Momamed, Thomas Krøigård, Thomas Agerbo Gaist, Lars Kjøbsted Markvardsen, Søren Hein Sindrup, Henning Andersen, Morten Blaabjerg

Aarhus University Hospital

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.

Translated title of the contribution	Antibodies in patients with chronic inflammatory demyelinating polyneuropathy
Original language	Danish
Article number	V08180526
Journal	Ugeskrift for Læger
Volume	181
Issue number	16
ISSN	0041-5782
Publication status	Published - Aug 2019

Documents & Links

http://ugeskriftet.dk/videnskab/antistoffer-hos-patienter-med-kronisk-inflammatorisk-demyeliniserende-polyneuropati

Cite this

@article{712d0f7ffcb24912bc4b22e7ba45199e,

title = "Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati",

abstract = "Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.",

author = "Momamed, {Abdullahi Ahmed} and Thomas Kr{\o}ig{\aa}rd and {Agerbo Gaist}, Thomas and Markvardsen, {Lars Kj{\o}bsted} and Sindrup, {S{\o}ren Hein} and Henning Andersen and Morten Blaabjerg",

year = "2019",

month = aug,

language = "Dansk",

volume = "181",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "16",

}

TY - JOUR

T1 - Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati

AU - Momamed, Abdullahi Ahmed

AU - Krøigård, Thomas

AU - Agerbo Gaist, Thomas

AU - Markvardsen, Lars Kjøbsted

AU - Sindrup, Søren Hein

AU - Andersen, Henning

AU - Blaabjerg, Morten

PY - 2019/8

Y1 - 2019/8

N2 - Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.

AB - Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 181

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 16

M1 - V08180526

ER -

Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati

Abstract

Documents & Links

Fingerprint

Cite this